Novel anticoagulants in the therapy of peripheral arterial and coronary artery disease

Current Opinion in Pharmacology

Volumn 13, Issue 2, 2013, Pages 294-300

  Jacomella, Vincenzo ^a   Corti, Natascia ^a   Husmann, Marc ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; ARGATROBAN; BETRIXABAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; CYTOCHROME P450 INHIBITOR; DABIGATRAN; DABIGATRAN ETEXILATE; EDOXABAN; GLYCOPROTEIN P INHIBITOR; HEPARIN; OTAMIXABAN; PLACEBO; QUINIDINE; RIVAROXABAN; THROMBIN INHIBITOR; VERAPAMIL; WARFARIN; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; ATHEROSCLEROTIC PLAQUE; BIOACCUMULATION; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FOOD DRUG INTERACTION; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCOAGULABILITY; ISCHEMIA; LIMB ISCHEMIA; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; THROMBOSIS; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; CORONARY ARTERY DISEASE; HUMANS; PERIPHERAL ARTERIAL DISEASE; THROMBOSIS;

EID: 84879416654     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2012.12.005     Document Type: Review

References (34)

1. U. Zeymer, K.G. Parhofer, D. Pittrow, C. Binz, M. Schwertfeger, T. Limbourg, and J. Rother Risk factor profile, management and prognosis of patients with peripheral arterial disease with or without coronary artery disease: results of the prospective German REACH registry cohort Clin Res Cardiol 98 2009 249 256
2. J.C. Bradberry Peripheral arterial disease: pathophysiology, risk factors, and role of antithrombotic therapy J Am Pharm Assoc (2003) 44 2004 S37 S44 (quiz S44-S35)
3. J. Saw, D.L. Bhatt, D.J. Moliterno, S.J. Brener, S.R. Steinhubl, A.M. Lincoff, J.E. Tcheng, R.A. Harrington, M. Simoons, and T. Hu The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials J Am Coll Cardiol 48 2006 1567 1572 (Pubitemid 44528177)
4. D.L. Bhatt, P.G. Steg, E.M. Ohman, A.T. Hirsch, Y. Ikeda, J.L. Mas, S. Goto, C.S. Liau, A.J. Richard, and J. Rother International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis JAMA 295 2006 180 189 (Pubitemid 43076437)
5. K.G. Smolderen, K. Wang, G. de Pouvourville, B. Bruggenjurgen, J. Rother, U. Zeymer, K.G. Parhofer, P.G. Steg, D.L. Bhatt, and E.A. Magnuson Two-year vascular hospitalisation rates and associated costs in patients at risk of atherothrombosis in France and Germany: highest burden for peripheral arterial disease Eur J Vasc Endovasc Surg 43 2012 198 207
6. L. Wallentin, R.C. Becker, A. Budaj, C.P. Cannon, H. Emanuelsson, C. Held, J. Horrow, S. Husted, S. James, and H. Katus Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
7. D.A. Morrow, S.D. Wiviott, H.D. White, J.C. Nicolau, E. Bramucci, S.A. Murphy, M.P. Bonaca, C.T. Ruff, B.M. Scirica, and C.H. McCabe Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel- Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction Circulation 119 2009 2758 2764
8. S. Anand, S. Yusuf, C. Xie, J. Pogue, J. Eikelboom, A. Budaj, B. Sussex, L. Liu, R. Guzman, and C. Cina Oral anticoagulant and antiplatelet therapy and peripheral arterial disease N Engl J Med 357 2007 217 227 (Pubitemid 47080386)
9. E.R. Mohler 3rd Atherothrombosis - wave goodbye to combined anticoagulation and antiplatelet therapy? N Engl J Med 357 2007 293 296
10. M. Hurlen, M. Abdelnoor, P. Smith, J. Erikssen, and H. Arnesen Warfarin, aspirin, or both after myocardial infarction N Engl J Med 347 2002 969 974
11. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial Lancet 355 2000 346 351
12. P. Alonso-Coello, S. Bellmunt, C. McGorrian, S.S. Anand, R. Guzman, M.H. Criqui, E.A. Akl, P. Olav Vandvik, M.G. Lansberg, and G.H. Guyatt Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e669S e690S
13. I. Ahrens, G.Y. Lip, and K. Peter New oral anticoagulant drugs in cardiovascular disease Thromb Haemost 104 2010 49 60
14. E.M. Conway Angiogenesis: a link to thrombosis in athero-thrombotic disease Pathophysiol Haemost Thromb 33 2003 241 248 (Pubitemid 40278690)
15. A.P. Owens 3rd, and N. Mackman Role of tissue factor in atherothrombosis Curr Atheroscler Rep 14 2012 394 401
16. R.R. Packard, and P. Libby Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction Clin Chem 54 2008 24 38 (Pubitemid 351182593)
17. M. Popovic, K. Smiljanic, B. Dobutovic, T. Syrovets, T. Simmet, and E.R. Isenovic Thrombin and vascular inflammation Mol Cell Biochem 359 2012 301 313
18. R. Loeffen, H.M. Spronk, and H. ten Cate The impact of blood coagulability on atherosclerosis and cardiovascular disease J Thromb Haemost 10 2012 1207 1216
19. J.L. Mega, E. Braunwald, S.D. Wiviott, J.P. Bassand, D.L. Bhatt, C. Bode, P. Burton, M. Cohen, N. Cook-Bruns, and K.A. Fox Rivaroxaban in patients with a recent acute coronary syndrome N Engl J Med 366 2012 9 19
20. J.H. Alexander, R.C. Becker, D.L. Bhatt, F. Cools, F. Crea, M. Dellborg, K.A. Fox, S.G. Goodman, R.A. Harrington, and K. Huber Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial Circulation 119 2009 2877 2885
21. F. Dentali, N. Riva, M. Crowther, A.G. Turpie, G.Y. Lip, and Ageno W Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature Circulation 126 20 2012 2381 2391
22. K.H. Mak Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials BMJ Open 2 5 2012 e001592
23. H. ten Cate Tissue factor-driven thrombin generation and inflammation in atherosclerosis Thromb Res 129 Suppl 2 2012 S38 S40
24. R. Kreutz Pharmacodynamic and pharmacokinetic basics of rivaroxaban Fundam Clin Pharmacol 26 2012 27 32
25. R. Agrawal, P. Jain, and S.N. Dikshit Apixaban: a new player in the anticoagulant class Curr Drug Targets 13 2012 863 875
26. P.C. Wong, E.J. Crain, B. Xin, R.R. Wexler, P.Y. Lam, D.J. Pinto, J.M. Luettgen, and R.M. Knabb Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies J Thromb Haemost 6 2008 820 829 (Pubitemid 351524543)
27. P. Prandoni Anticoagulant treatment of pulmonary embolism: impact and implications of the EINSTEIN PE study Eur J Haematol 89 2012 281 287
28. H.R. Buller, M.H. Prins, A.W. Lensin, H. Decousus, B.F. Jacobson, E. Minar, J. Chlumsky, P. Verhamme, P. Wells, and G. Agnelli Oral rivaroxaban for the treatment of symptomatic pulmonary embolism N Engl J Med 366 2012 1287 1297
29. E. Romualdi, M.P. Donadini, and W. Ageno Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study) Expert Rev Cardiovasc Ther 9 2011 841 844
30. J.H. Alexander, R.D. Lopes, S. James, R. Kilaru, Y. He, P. Mohan, D.L. Bhatt, S. Goodman, F.W. Verheugt, and M. Flather Apixaban with antiplatelet therapy after acute coronary syndrome N Engl J Med 365 2011 699 708
31. J. Oldgren, A. Budaj, C.B. Granger, Y. Khder, J. Roberts, A. Siegbahn, J.G. Tijssen, F. Van de Werf, and L. Wallentin Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial Eur Heart J 32 2011 2781 2789
32. R. De Caterina, S. Husted, L. Wallentin, F. Andreotti, H. Arnesen, F. Bachmann, C. Baigent, K. Huber, J. Jespersen, and S.D. Kristensen New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper J Am Coll Cardiol 59 2012 1413 1425
33. K. Uchino, and A.V. Hernandez Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials Arch Intern Med 172 2012 397 402
34. P.G. Steg, S.R. Mehta, J.W. Jukema, G.Y. Lip, C.M. Gibson, F. Kovar, P. Kala, A. Garcia-Hernandez, R.W. Renfurm, and C.B. Granger RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome Eur Heart J 32 2011 2541 2554